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Non-nutritive sweetener (NNS) use has increased exponentially over the last 
30 years as industrialized countries attempted, and failed, to battle obesity epi-
demics. Large studies have now shown that consumption of NNS’s does not help 
obese individuals lose weight. A large number of scientific studies on NNS’s effects 
have many conflicting results, methodological issues, conflicts of interest, while 
double blind studies represent a small minority of the studies. NNS’s have often 
been considered as a group despite having unique in vivo absorption, distribution, 
metabolism, and excretion (ADME). Aspartame may be the most desirable NNS 
due to its rapid degradation in vivo, whereas saccharin and sucralose are worrisome 
due to their extended stability in vivo. This review will focus on the most ubiqui-
tous NNS’s: aspartame, saccharin, acesulfame-K, sucralose, stevia, sugar alcohols 
(sorbitol, xylitol, and erythritol), and discuss their different chemical structures, 
metabolism, effect on the gut biome and cancer.
Keywords: artificial sweetener, sweet receptor, gut brain axis, obesity, diet
1. Introduction
Non-nutritive sweeteners (NNS’s) contain few to no calories or nutrients. As 
obesity had been rising in western countries at the end of the 20th century, NNS use 
increased 54% in adults and a staggering 200% in children from 2000 to 2010 [1, 2]. 
In 2018 over $7 billion (USD) NNS’s (also called artificial sweeteners or sugar substi-
tutes) were sold which is projected to grow 5%/year reaching more than $10 billion 
by 2025 [3]. However recent reports have shown NAS’s to be ineffective at reducing 
obesity [4, 5], which is their primary health target. Malek et al. found that while 
consumers of NNS’s reported lower caloric intake compared to non-NNS consum-
ers, the NNS consumers were more overweight and obese [4]. While the “Calories 
in - Calories Out” (CICO) paradigm governing net weight gain/loss of has been 
resoundingly confirmed [6–8], the mechanism causing NAS’s to be ineffective at 
reducing weight are still being investigated. Does NAS consumption cause increased 
appetite for food with caloric content (calories in)? Is metabolism and movement 
decreased (calories out)? Are effects mostly due to human cellular or gut microbi-
ome response? How consistent are these effects across the NNS’s, and lastly how 
individual are these effects? Genetic polymorphisms have been elucidated which do 
personalize an individual’s experience to NAS’s [9, 10], but this does not appear to be 
a primary driver since obesity has risen on a population and indeed global level.
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The safety thresholds for human consumable substances are set by national 
or international organizations, and this review will highlight the work done by 
three organizations: the Joint Expert Committee on Food Additives (JECFA), 
European Union’s Scientific Committee for Food (SCF), and the US Food and Drug 
Administration (FDA). Eight NNS’s have been approved by the FDA: aspartame, 
acesulfame potassium, luo han guo (monk) fruit extract, neotame, saccharin, 
stevia, sucralose and advantame [11]. While this group, along with sugar alco-
hols, are often grouped as sugar replacements they differ in their in vivo stability, 
targets, and even caloric content to a minor extent. The differences between their 
structures, metabolism, effect on gut biome, host metabolism, obesity, cancer, and 
future human studies will be discussed.
2. Biological effects of artificial sweeteners
Non-nutritive sweeteners (NNS’s) were designed to mimic the sweetness of 
sugar without containing any caloric content. However, over the last 40 years 
robust biological effects have been demonstrated beyond the desired sweetness 
profile. Artificial sweeteners differ in structure, in vivo half-life, molecular targets, 
effect on host gut-biome, and magnitude of biological effect. Consumer products 
increasingly have mixed NNS’s to augment their flavor profile, which makes survey 
study results less useful since questions such as “how many diet sodas did you drink 
per week” can encompass biological responses from an unknown mix of NNS’s. The 
specific attributes and effects for the major NSS’s will be reviewed below.
2.1 Structure and metabolism of artificial sweeteners
While Non-nutritive sweeteners (NNS’s) have a detectably different flavor 
profile [12, 13], they largely overlap in successfully replacing the sensation of sugar 
in foods and beverages. As a group NNS’s are much more potent at stimulating the 
sensation of sweetness in the mouth compared to table sugar. There is concern 
that such swamping of one’s taste receptors with sweetness through excessive 
NNS consumption could limit the desirability of more complex flavors, making 
less sweet food (e.g. fruit) less appealing, and causing healthy unsweet foods (e.g. 
vegetables) to be newly intolerable. NNS’s differ in chemical structure by over 
5-fold in molecular weight (MW) (Table 1). Saccharin is the lightest at 183 MW, 
while Rebaudioside A (a steviol glycoside) is a whopping 967 MW which causes 
stevias elimination (urine vs. feces) to differ between mammals based on billary 
excretion MW thresholds [17, 18]. The safety of NNS’s are initially determined 
from taxoicokinetic studies in various animal models, such as mice and rats, which 
absorption, distribution, metabolism, and excretion (ADME) after ingestion. 
The animal model with results that most closely match the ADME characteristics 
seen during human consumption are used to set safety limits. A wide range of 
NNS concentrations are used so the high doses can elucidate any adverse effects, 
while the lower doses titrate these potential adverse effects away until the “no 
observed adverse effect level” (NOAEL) is determined. Adverse effects measured to 
determine NOAEL may include changes in development, morphology, growth, or 
lifespan. The NOAEL is used to determine the acceptable daily intake (ADI), which 
is usually set at 100 times lower than the NOAEL. Therefore, while the ADI is often 
misinterpreted as a “line in the sand”, a level above which a compound is instantly 
toxic. However, in reality the ADI is a warning level that should be much lower than 
toxicity while allowing up to a two fold increase before deleterious effects are seen. 
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Name Saccharin Sucralose Aspartame Stevioside Acesulfame-K Neotame Advantame Cyclamate Sugar alcohols
Main site of 
metabolism
None None GI tract Liver None Entire body None Gut biome Liver
ADI (mg/
kg/day)
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ADI = Accepted Daily Value.
*Number of Tabletop Sweetener Packets a 60 kg (132 pound) person would need to consume to reach the ADI. Calculations assume a packet of high-intensity sweetener is as sweet as two teaspoons of sugar.
Adapted from: Kim Y, Keogh JB, Clifton PM. Non-nutritive Sweeteners and Glycaemic Control. Curr Atheroscler Rep. 2019 19;21(12):49. [16]
**ADI (# 12 oz. sodas) was calculated for a 60 kg person, using the following brands and concentrations: 90 mg saccharin in Tab; 60 mg sucralose in Diet Coke with Splenda; 187 mg aspartame in Diet 
Coke; 45 mg acesulfame-K in Diet Coke with Splenda. Note splenda and acesulfame-K are mixed in multiple diet beverages such as Diet Coke with Splenda shown in this table.
? The mg of NNS could not be found for commercially sold drinks with stevioside, neotame, advantame, cyclacate, sugar alcohols.
Table 1. 
Comparison of non-nutritive sweetener characteristics.
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caloric balance, such as increased caloric consumption due to unbalanced sweetness 
perception, would likely not be discovered in an initial NOAEL study.
There are synthetic sweeteners (acesulfame K, aspartame, cyclamate, saccharin, 
neotame, advantame, and sucralose), natural sweeteners (thaumatin, steviol glu-
cosides, monellin, neohesperidin dihydrochalcone, and glycyrrhizin), and nutritive 
sweeteners (polyols or sugar alcohols). In 2017 the world consumed 159,000 metric 
tons of NNS’s (valued at $2 billion USD). China was the top region consuming 
NNS’s (32%) followed by Asia/Oceania (23%), United States (23%), Europe (12%), 
and then Africa (7%) [19]. The NNS most used in food and drink was aspartame, 
followed by saccharin, acesulfame, and sucralose (18.5, 9.7, 6.8, and 3.3 thousand 
metric tons respectively) [20]. With the quantities of NNS being produced and 
consumed both increasing rapidly, their contamination in the environment has 
been of concern [21]. There has been quantitative reports finding NNS’s in surface 
water (e.g. lakes, rivers, streams), groundwater, tap water, discharge into the sea, 
and even in the atmosphere [22], as well as passing through Waste Water Treatment 
Plants (WWTPs) [23]. NNS’s have been found to interfere with photosynthesis, 
creating disturbances in carbon dioxide intake [24], and decreasing sugar break-
down in human body [25, 26]. The exposure to any of these environmental NNS’s 
would likely be orders of magnitude lower than current self-selected consumption 
levels. Acesulfame-potassium (Ace-K) was investigated, as an environmentally 
persistent NNS due to low biodegradation, and found to not pose an environmental 
risk with very low levels in surface water and even less in groundwater (lower parts 
per billion [ppb] range and lower parts per trillion [ppt] respectively) [27].
The metabolism of the main NNS’s can largely be put into 3 bins [28]: aspartame 
which is broken up when it hits the GI tract, artificial sweeteners that enter the GI 
tract (stevia, cyclamate, sucralose, acesulfame potassium), and sugar alcohols which 
can contribute calories to the diet. Cyclamate is not used in the US, and not widely 
used in Canada due to concerns about carcinogenesis. Advantame and neotame being 
newer compounds to the market also do not represent a large portion of the market.
2.1.1 Aspartame
Aspartame is 200 times sweeter than sugar, the most ubiquitous of the NNS’s, 
and is quickly digested into aspartic acid, phenylalanine, and methanol. Due to 
its amino acid constituency aspartame is strictly a nutritive sweetener. However, 
because 100 g of sugar can be replaced by less than a gram of aspartame, it is con-
sumed in such low levels that it is considered as a NNS [29]. The phenylalanine can 
build up to toxic levels in those with a rare genetic defect, phenylketonuria (PKU) 
present for 1 in 12,000 births [30], caused by mutations and lower levels in the 
enzyme phenylalanine hydroxylase (PAH). Infants are diagnosed with PKU shortly 
after birth and avoiding aspartame is achieved well by patients throughout life [31]. 
However, people with PKU do show increased oxidative stress [32] and the presence 
of comorbidities including asthma, alopecia, urticaria, gallbladder disease, rhinitis, 
esophageal disorders, anemia, overweight, GERD, eczema, renal insufficiency, 
osteoporosis, gastritis/esophagitis and kidney stones [33]. Methanol, which is con-
verted to formaldehyde (a known carcinogen) [34], is often pointed to as a reason 
to avoid aspartame, but higher levels of methanol are consumed when eating fruit 
[35, 36]. The FDA set the ADI of aspartame at 50 mg/kg/day and, despite consump-
tion increases since the 1980s, the US average and 95th percentile intake in 2013 was 
4.9 and 13.3 mg/kg/day respectively, showing consumption levels are still 4 fold 
below the ADI. While some customers have complained of an aspartame sensitivity 
a double blind study found there to be no evidence of any acute adverse response 
[37]. Aspartame holds a unique position among NNS’s in that its pharmacophore 
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structure which binds sweet receptors is obliterated by esterases and peptidases 
shortly after consumption when it enters the gastrointestinal (GI) tract. Many of 
the NNS’s have been shown to bind sweet receptors outside of the oral cavity, such 
as in the digestive tract. Among all the NNS’s consumers can be most confident that 
aspartame will not elicit endogenous sweet receptor cascades after swallowing due 
to its rapid degradation early in the GI tract (Figure 1).
2.1.2 Saccharin
Saccharin was one of the leading NNS’s used during the early increase in global 
consumption (along with aspartame), but lost market share in the 1980s due to 
a 1978 paper suggesting rats had an increase in carcinomas in their urinary blad-
der upon exposure [38]. Since then studies have shown saccharin does not cause 
urinary cancer in humans and the carcinoma in mice may have been due to the 
large amounts of sodium administered (as sodium saccharin) [39]. Saccharin has 
a pKa of 1.8 and is absorbed better in species with a low stomach pH (e.g. rabbits 
and humans compared to the higher pH in rats). Being very water soluble there 
is no build up of saccharin in tissues. In humans ~90% is absorbed and excreted 
Figure 1. 
Metabolism and excretion of non-nutritive sweeteners. NNS’s differ in their in vivo stability, distribution, and 
excretion. Acesulfame-K, saccharin, stevia enter the bloodstream and are mostly excreted in the urine. Sucralose 
exists via the feces but can accumulate in fat when in an acetylated form. Red box: Site of metabolism where 
NSS is degraded. Black double box: Site of distribution or accumulation. Dashed red box: Site of elimination.
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in the urine while only ~10% exits in the feces. Discovered in 1878, saccharins 
use started to increase around 1900 when it was initially used as a sweetener by 
diabetic patients, but during the world wars its use in food increased because there 
were sugar shortages [40]. The stability of saccharin decreases above 125°C which 
diminishes its usefulness in cooking [40]. Saccharin is 300-fold sweeter than sugar, 
1.5-fold sweeter than aspartame, and even among heavy consumers (~2 mg/kg/
day) [41, 42] its usage levels are below the ADI of 5 mg/kg/day [43]. While sac-
charin requires less of a dose than aspartame to attain the same sweetness, it does 
have an undesirable metallic taste at high concentrations [44]. Saccharin can cross 
the placental barrier in rats, monkeys, and humans with maternal tissues having 
higher steady-state levels than the fetus, though the concentration in the fetal 
tissue does decrease slower than in maternal tissues. Therefore, mothers do not 
need to be as concerned with saccharin building up in their fetus, but if lowering 
consumption there will be a delay in lowering levels in the fetus. Of note, while 
saccharin buildup itself may not be an issue for the fetus, the effect of NNS’s on the 
maternal metabolism can have knock-on effects which do seem to affect the fetus. 
Consistent NNS consumption is associated with glucose intolerance, interference 
with energy homeostasis [45–47], and if occurring during pregnancy is associated 
with increased chances of obesity for the child after birth [46–48].
2.1.3 Acesulfame-K
Acesulfame potassium (Ace-K) is a non-nutritive sweetener discovered in 1967 
when a researcher accidentally tasted a new synthesis compound. Often labeled as 
one of the more pleasant tasting NNS’s (no metallic taste), Ace-K is commercially 
attractive due to its 200-fold greater sweetness than sugar, along with excellent 
solubility and stability in water [49, 50]. Multiple organizations (JECFA in 1983, 
SCF in 1985, and the FDA in 1988), agreed that there were no adverse effects in 
either rats or dogs over a 2-year period when fed up to 3% Ace-K [43]. Using the 
body weights this led to NOAELs of 900 and 1500 mg/kg/day for dogs and rats 
respectively. The JECFA and FDA used the rat study to set the ADI at 15 mg/kg/
day while SCF used the dog study to set the ADI at 9 mg/kg/day [51]. Ace-K is not 
metabolized in humans, but can degrade into acetoacetamide. Radiolabeling studies 
showing intact Ace-K (and zero breakdown products) in serum, urine, feces and/
or bile [43, 50, 51]. In humans 98% of a 30 mg Ace-K dose was excreted in urine 
within 24 hours. In pregnant women 1.6% of radiolabeled Ace-K was excreted in 
milk in 24 hours, which dropped by an order of magnitude the next day (to 0.16%). 
The highest Ace-K concentration (0.4 mg/kg) occurred in humans 1.5 hours after 
consumption [52].
2.1.4 Sucralose
Recently a study in rats has shown that sucralose (80 mg/kg/day for 40 days) 
converted to acetylated forms of sucralose, which are less polar, deposit in fat 
tissue due to their lipophilicity (Figure 1). These acetylated sucralose compounds 
were detected 6 days after unmodified sucralose had left the body. The original 
studies and regulatory decision process were unaware of these metabolites or 
accumulation in adipose tissue due to use of a methanol fraction from feces for 
analysis [27]. Sucralose is a chlorinated carbohydrate, which has been found to 
persistently exist in wastewater treatment plant effluents and downstream aquatic 
environments. Free chlorine, ozone, and ferrate did not degrade sucralose in 
water, but strong oxidizing agent hydroxyl radicals (•OH) was able to degrade 
sucralose in water [53].
Sugar Intake - Risks and Benefits
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In animal and human studies sucralose has been shown to not have carcinogenic 
activity, even when consumed at doses several orders of magnitude more than 
normal consumption levels [54]. Sucralose largely passes through the digestive tract 
and is eliminated in feces unchanged (85%) [54]. The remaining 15% of sucralose 
does distribute throughout the body, but because there is not active transport there 
are not significant levels in breast milk or across the blood–brain barrier into the 
central nervous system. There is 2–3% of consumed sucralose undergoing phase 
II metabolism (glucuronidation) and, along with the other 12% that was initially 
retained, is excreted in the urine [55–57].
2.1.5 Stevia
Stevia is not absorbed, whereas cyclamate and sucralose are partially absorbed 
but still not metabolized. Steviol glycosides and luo han guo fruit extracts are 
categorized as natural sweeteners by the FDA and therefore regulated differently 
[58]. Steviol glycosides are actually a group of compounds which are metabolized 
differently with varying biological effects, and while usually derived from the 
Stevia rebaudiana Bertoni plant, can also be produced via fermentation [59]. All 
steviol glycosides share a common chemical core structure, diterpene steviol 
(the final product of colonic bacterial metabolism). The Joint Expert Committee 
on Food Additives (JECFA) established an upper acceptable daily intake (ADI) 
of 2 mg/kg/day based on the amount of steviol after digestion which has been 
termed the “steviol equivalent”. For example, 3 mg of rebaudioside A converts 
to just 1 mg of steviol equivalent. Steviol glycosides are not metabolized in the 
upper gastrointestinal tract, but once reaching the colon bacteria convert them 
to steviol compounds which travel to the liver and are glucuronidated to steviol 
glucuronide [24] (Figure 1). Increasing levels of steviol glucuronide can be 
detected to peak in the plasma in humans 8 hours after administration, with a 
half-life of ~14 hours. In rats almost all of radiolabeled steviol glycosides were 
found in feces, with less than 2% showing up in urine [25]. However in humans 
steviol glucuronide was excreted in urine not feces, due to a difference in biliary 
excretion molecular weight thresholds compared to rats [17, 18]. The glucose that 
is removed from the glycosides in the colon is not absorbed as caloric input by 
humans, and is assumed to be quickly consumed by the colonic bacteria.
2.1.6 Sugar alcohols (sorbitol, xylitol, and erythritol)
While sugar alcohols (sorbitol, xylitol, and erythritol) are often binned with all 
of the sugar substitutes, they are not actually NNS’s since they do contribute usable 
calories for humans. Sorbitol, xylitol, and erythritol are carbon chains with an 
alcohol attached to each carbon and differ structurally only in their carbon length 
with 6, 5, and 4 carbons respectively (Table 1). Sorbitol has low absorption, is 
hyperosmotic causing laxative effects, and is metabolized to fructose (via sorbitol 
dehydrogenase). Xylitol has low absorption in the GI tract, and is processed in the 
pentose phosphate pathway (PPP). Erythritol is absorbed but not metabolized and 
has negligible calories compared to sorbitol or xylitol. Generally the NNS’s do not 
increase blood glucose levels with an exception being xylitol and maltitol which 
increase blood glucose about 40% and 80% as much as sugar respectively [24].
2.2 Effect on gut biome
The human body has been estimated to have 10-fold more bacterial symbiotic 
cells than human cells. The gut microbiome contains 1014 microorganisms that play 
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a role in host nutrition, proliferation of intestinal cells, bone mineralization, xeno-
biotic metabolism, immune system regulation and protection against pathogens 
[60]. The effect of NAS of gut microbiome is clearly augmented by multiple NAS 
and could be responsible for a significant fraction of the negative population level 
obesity increases. In an elegant paper Suez et al. showed NAS consumption led to 
glucose intolerance through induction of compositional and functional alterations 
to the intestinal microbiota [61]. Mice fed saccharin, sucralose, or aspartame all 
showed increased blood glucose during an oral glucose test (>250 mg/dl at 15 min. 
Vs 200 mg/dl for sucrose or glucose), as well as increased area under the two-hour 
blood glucose response curve (AUC) after 11 weeks of consuming NAS. These 
deleterious effects were abrogated by antibiotic treatment, but were fully transfer-
rable to germ-free mice upon fecal transplantation of microbiota configurations 
from NAS-consuming mice. Saccharin exhibited the greatest glucose intolerance 
and was further studied. Interestingly mice fed saccharin did not show differences 
in liquid or chow consumption, oxygen consumption, walking distance or energy 
expenditure. In contrast the gut microbiome of the mice fed saccharin did change 
significantly, with more than 40 operational taxonomic units (OTUs) significantly 
altered in abundance. Taxa that increased in relative abundance belonged to the 
Bacteroides genus and Clostridiales order, while other members of the Clostridiales 
order comprised the majority of under-represented taxa, along with Lactobacillus 
reuteri, with similar effects in germ-free recipients of stools from saccharin-
consuming donors [61]. A similar NAS-induced dysbiosis and glucose intolerance 
was demonstrated in healthy human subjects (based on a validated food frequency 
questionnaire) [61]. However Ruiz-Ojeda et al. (2019) reviewed the NNS’s and 
found only sucralose, saccharin, and stevia to have evidence of effecting the gut 
microbiota. Sucralose could cause dysbiosis by lowering the total number of bifi-
dobacteria, lactobacilli, Bacteriodes, and Clostridiales (both aerobic and anaerobic 
species) [62]. A study in 2017 found sucralose could increase Clostridium cluster 
XIVa in mice [63]. A positive correlation was found between NAS consumption 
and multiple metabolic-syndrome-related clinical parameters including: increased 
weight and waist-to-hip ratio (measures of central obesity), higher fasting blood 
glucose, glycosylated hemoglobin (HbA1C% indicative of glucose concentration 
over the previous 3 months) and glucose tolerance test (GTT, measures of impaired 
glucose tolerance). A small study was also done following seven healthy non-NAS 
consuming volunteers for 1 week (5 males and 2 females, aged 28–36) in which they 
consumed the FDA’s maximal acceptable daily intake (ADI) of commercial saccharin 
(5 mg/kg body weight, as 120 mg x 3times/day) and were monitored by continuous 
glucose measurements and daily GTT. Even in the short 7-day exposure period, most 
individuals (4 out of 7) developed significantly poorer glycaemic responses [61].
Consuming larger amounts of non-caloric artificial sweeteners (NAS) have 
been found to increase in hemoglobin (HbA1C %), as well as increased levels of 
Enterobacteriaceae family, Deltaproteobacteria class, and Actinobacteria phylum 
found in fecal microbiota [61]. There have been literature reviews that found such 
effects to be inconsistent with methodological or reporting problems concluding 
that NAS’s (e.g., acesulfame K, aspartame, cyclamate, neotame, saccharin, sucra-
lose, steviol glycosides) have no evidence of an actual adverse effect on human 
health [64]. Such reviews often point out that studies showing changes in the diet 
unrelated to NAS consumption may be confounding the data. It is worth noting 
that such studies can be funded by corporate entities with conflicts of interest, such 
as the Calorie Control Council (established in 1966 as an international association 
representing the low- and reduced-calorie food and beverage industry) [64]. A 2016 
systematic study on risk of bias screened 493 papers publishing about NNS and, 
after analyzing the 31 papers that met the eligibility requirements, found extremely 
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statistically significant bias [65]. Reviews that were sponsored by the artificial 
sweetener industry were 1700% more likely to have favorable results (Relative Risk 
(RR) = 17.25). Not only do industry reported papers supporting the use of NNS’s 
seem unreliable, but all 4 papers analyzed that were funded by NNS competitor 
companies (sugar and water industry) found unfavorable conclusions. A disturbing 
42% of reviews did not have authors’ financial conflicts of interest disclosed. Lastly 
reviews performed by authors with financial conflicts of interest almost always had 
favorable conclusions (18/22, RR = 7.36) [65].
Aspartame and acesulfame-K have been found to not interact with the human 
colonic microbiota, whereas saccharin and sucralose change the gut microbiome 
populations (though those effects are not clearly positive or detrimental) [66]. 
Sugar alcohols can also reach the colonic microbiota and act as prebiotics, with 
accompanying negative laxative effects [67], particularly in patients with inflam-
matory bowel syndrome (IBS). Since sucralose can deposit in fat tissue in an 
acelatyed version (see metabolism section), studies that have looked at the effect of 
sucralose with less than a week washout period could have to be revisited [68].
While most studies have just measured disturbances or lack thereof from NNS’s 
there have been some advancements in the physiological and mechanistic effects gut 
microbiome dysbiosis could cause. One leading concern would be if NNS’s can lead 
t0 Non-alcoholic fatty liver disease (NAFLD). NAFLD is denoted by an excess fat in 
the liver in people who do not drink significant alcohol. Gut dysbiosis has a con-
tinually increasing number of known effects including altering caloric absorption 
[69], development of a “leaky gut”, increase in bile acid receptors and transporters, 
as well as choline deficiency. A leaky gut allows proinflammatory molecules and 
bacterial endotoxins (e.g. LPS and ethanol) to enter the bloodstream, travel through 
the portal vein to the liver and increase hepatic inflammation which leads to 
NAFLD. Increases in bile acid lead to insulin resistance and NAFLD [60]. Dysbiosis 
in the gut increases conversion of choline to dimethylamine (DMA) and trimethyl-
amine (TMA) [70, 71], potentially leading to choline deficiency which decreases the 
transportation of VLDL which is used to mobilize fat from the liver [60].
2.3 Effect on host metabolism and obesity
Glucose (which NSS’s mimic) has long been known as the in vivo “nutrient 
sensor”, not only for carbohydrates consumed but as a “fed state” signal in general 
since muscular protein can be broken down to produce glucose (via gluconeogen-
esis). However it appears that the dose dependent glucose detection of sweetness, 
which matches the caloric load of that glucose, is also an important input for our 
in vivo nutrient sensor. Recent evidence suggests NNS consumption disrupts our 
normal association if sweetness levels detected differ from caloric intake, causing 
us to crave even more sweets and gain weight. Indeed, the San Antonio Heart Study 
found those who drank more than 21 diet drinks per week were found to be twice as 
likely to become overweight or obese as people who did not drink diet soda [72].
2.3.1 Sweetness and caloric load alignment for maximal metabolic response
A ground breaking study by Veldhuizen et al. found that for carbohydrate 
reward to maximize its biological response the level of sweet taste must match the 
caloric load that natural carbohydrate food would provide [73]. The level of caloric 
load was manipulated using maltodextrin, a tasteless carbohydrate, while the 
sweetness levels were manipulated with the NNS sucralose. Beverages with differ-
ing amounts of maltodextrin + sucralose showed a non-linear response between 
caloric load, metabolic response and reinforcement potency. When sweetness 
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is proportional to caloric load greater metabolic responses are observed. Lower 
calorie beverages were able to produce greater metabolic response than a beverage 
with more calories but the same level of sweetness, and that data was integrated in 
the Central Nervous System (CNS). fMRI studies showed the nucleus accumbens 
(NAcc) response was also greatest when sweetness and caloric load were balanced 
[73]. It understandably appears humans have evolved to elicit a maximum metabolic 
response to carbohydrate when the caloric load matches the sweetness that natural 
sugars such as glucose induce. The use of NNS’s are almost always used to replace 
the sweetness lost when calories are removed from processed foods or beverages, 
which is now know to elicit a submaximal metabolic response.
2.3.2 Nutrient sensing
Approximately 1% of the mucosal epithelial layer of the gastrointestinal (GI) 
tract are made up of hormone-secreting enteroendocrine (EE) cells, which by mass 
are the largest endocrine tissue in the body. It is now understood that whole-body 
metabolism integrates signals from many metabolically active tissues (GI tract, 
pancreas, adipose tissue, liver, and the CNS). These organs can release both nutri-
ent storage hormones in the fed state postprandially (e.g. glucagon-like peptide-1 
(GLP-1), gastric inhibitory peptide (GIP, also known as: glucose-dependent insuli-
notropic polypeptide), peptide tyrosine tyrosine (PYY), Cholecystokinin (CCK), 
Oxyntomodulin (OXM)) or after a period of fasting (e.g. ghrelin, 5-hydroxytrypta-
mine (5-HT, also known as gut-derived serotonin when released by the intestine)). 
Agonists of the sweet taste receptors in the GI tract modifies secretion of GLP-1, 
PYY, ghrelin, and GIP which appears to increase the storage of blood glucose [5] 
(to glycogen or triacylglycerides and preferential differentiation into adipocytes) 
[58]. Glucose causes GLP-1 secretion via glucose-dependent Na+ uptake via SGLT-1 
and intracellular glucose metabolism, closing the KATP channels, causing further 
depolarisation and exocytosis [74]. The distal portion of the small intestine in 
particular regulates glucose uptake via release of incretins (GLP-1, GIP) [74]. While 
many of these hormonal links to metabolic syndrome have been elucidated, such as 
increased 5-HT gut-derived serotonin levels in type II diabetics, most of the knowl-
edge covers the correlation of hormone levels with disease and the downstream 
effects (such as increased lipogenisis) but not the breadth and magnitude of molec-
ular mechanisms causing this. For example, while serotonin is most often thought 
of for its neurotransmitter effects in the CNS, more than 90% of whole body 5-HT 
levels are produced in enterochromaffin (EC) cells in the intestinal epithelium lin-
ing and platlets. These EC cells in the gut lumen detect multiple nutritional moieties 
such as glucose and fructose [75, 76], medium chain fatty acids, as well as various 
tastants and olfactants [77]. Studies of such EC cell stimulation are confounded by 
the fact that they are also regulated by mechanical stimulation, neural and endo-
crine inputs (e.g. adrenergic stimulation and GABA and somatostatin inhibition) 
[78]. The increased gut-derived 5-HT during a fasted state, along with glucagon, 
increases hepatic gluconeogenesis and glycogenolysis and therefore glucose output 
from the liver, while also inhibiting glucose uptake or glycogen synthesis at the liver. 
At the same time 5-HT increases lypolysis in white fat cells.
Under fasting conditions, gut-derived 5-HT, together with glucagon, mark-
edly increases hepatic glucose output, a main driver of fasting euglycaemia, by 
increasing hepatic gluconeogenesis and glycogenolysis (29), while inhibiting 
glucose uptake and glycogen synthesis in the liver (30). 5-HT promotes not only 
lipolysis, but also energy conservation and weight gain via reduced thermogenesis 
in brown adipose tissue (and hence reduced energy expenditure) [79]. Antagonists 
and agonists of these caloric receptors, such as NNS’s, have to be considered in the 
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hormone secretion per cell. However as an example, HT-5 also increases the density 
or glucose-sensitivity of duodenal EC cells, which can be measured in obese human 
duodenal EC cells [80], but the molecular mechanisms producing this increased 
density have not been elucidated.
Because adipocytes (both undifferentiated and mature) express sweet and bitter 
taste receptors [69], a direct role of NNS’s in adipocyte differentiation and function 
is likely. Both acesulfame-K and saccharin bind the bitter taste receptors at higher 
concentrations adding the complexity of a second pathway they stimulate compared 
to many other NNS’s [70]. Sucralose was found to promote fat accumulation and 
upregulate adipogenesis, inflammation, and antioxidant pathways [71]. While 
rodents lacking sweet taste receptor subunits were shown to have less adiposity and 
smaller adipocytes on a Western diet [32], showing the importance of sweet taste 
receptor signaling for normal adipose tissue development. One study suggested 
NNS’s were not dependent on sweet taste receptors to stimulate adipogenesis or sup-
press lipolysis [36]. However in contrast, Masubuchi et al. reported that adipogenesis 
was inhibited by sucralose and saccharin in preadipocytes [72], and suggested NNS 
exposure leads to microtubule disassembly and alteration of the PI3K–Akt signaling 
pathway [72]. The rodent and in vitro studies do not provide conclusive results [58].
A pattern has emerged in which observational studies make NNS’s appear harm-
ful causing increased weight, while intervention studies find NNS’s reduce weight. 
A natural hypothesis was that in the observational studies the people consuming 
NNS’s must have compensated by eating more solid food calories at subsequent 
meals, which indeed was found in some studies, but others reported a reduction 
in total energy expenditure after NNS consumption [81]. When sweet receptors 
in the oral cavity are activated not only does the brain perceive sweetness but the 
body prepares to digest calories through the cephalic phase responses, most notably 
the cephalic phase insulin response (CPIR) which is a neurally-mediated release of 
insulin prior to nutrient absorption [82]. Not only do glucose [83] and sucrose [82] 
stimulate CPIR, but saccharin [82] and possibly sucralose [84] also to activate CPIR. 
Of note, all these molecules which activate CPIR seem to bind the same VFD region 
on the T1R3 receptor [84]. In contrast aspartame [84, 85], stevioside and cyclamate 
[86] all bind a different site on the receptor and fail to elicit the CPIR response. If 
this CPIR were the main driver of obesity and driven by binding the VFD region 
on T1R3 then those consuming saccharin and sucralose would be expected to have 
increased Total Body Weight (TBW) compared to those consume aspartate, stevio-
side, or cyclamate. However, that has been neither proven nor disproven. In addi-
tion while CPIR may be activated through the sweet receptor recent studies have 
suggested that CPIR may actually be activated through the adenosine triphosphate 
(ATP)-sensitive potassium channel (KATP channels) [87] which are also found on 
T1R3-containing taste cells [88].
The magnitude with which the combination of circadian rhythm and eating controls 
metabolism at a cellular level is currently a productive field of research. The use of NSS’s 
during fasting would be useful to not only elucidate the pathways augmented by NNS’s 
while removing confounding variables, but would also shed some needed information 
on to what degree, if any, NNS’s inhibit the positive molecular effects of fasting. It is 
now well documented that extended fasts (> = 1 day) increase autophagy (recycling 
of cellular content) [89–93] which has been shown to be anti-cancer [94], anti-aging 
[93, 95–100], beneficial to sleep [101–103], protective of muscle loss [89, 104], and 
clearly helpful to reduce weight [105–109]. Many people that undergo intermittent 
fasting still consume diet beverages because they are viewed as low or zero calorie. 
Quality-Adjusted Life Years (QALYs) analyses for NNS’s, incorporating data across 
multiple disease states, would be useful in determining the utility of NSS’s (e.g. posi-
tive tastant stimulant vs. negative microbiome modulator). The main QALY studies 
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found in pubmed by the author concerned the efficacy of sugar taxes to increase QALYs 
[110–113]. Sirtuin 1 (SIRT1) is a deacetylase involved in normal circadian rhythm 
modifications, has been linked to increasing longevity, and increases with fasting. 
Recently NNS’s (aspartame and saccharin) were used to suggest the metabolic effects of 
sugars (not perception of sweetness) resulted in the SIRT1 regulation of a simple sugar 
preference [114]. It is unknown if NNS consumption during fasting effects such calorie 
specific pathways as quality of sleep, autophagy, mTOR inhibition, muscle sparing 
during exercise, or increased efficacy of cancer therapy.
2.4 Effect on cancer
Non-nutritive sweeteners (NNS’s) have had a rollercoaster history in being 
viewed at either increasing or decreasing lifespan, with quality of life being less 
often measured. An early study by Reuber in 1978, which received tremendous 
attention in the popular press, appeared to show very high levels of saccahrin caus-
ing bladder cancer in rodents [38]. However, earlier and later studies did not support 
this conclusion and mechanistic data [115] showed different saccharin metabolism 
in rodents and humans [39, 116, 117]. Yet as a result of the Reuber study, saccharin 
was listed from 1981 to 2000 as a substance reasonably anticipated to be a human 
carcinogen in the U.S. National Toxicology Program’s Report on Carcinogens [118, 
119]. Since 2000 the view of NNS’s has increasingly become Generalized Recognized 
as Safe (GRAS). This continued for maybe 15 years, until recent data showing a fail-
ure to reduce obesity has again ramped up questions regarding their utility. However 
large cohort studies of NNS consumption showed all-cause mortality to increase in 
a range from 4% [120] - 24% [121]. The correlation with increased risk from cardio-
vascular (13% [120]) and circulatory disease (52% [121]) was higher.
Recent data suggests that NNS’s may actually be beneficial in the treatment of 
cancer patients [122, 123], in contrast to the earlier attention to carcinogenicity or 
current concern over obesity in the general public. Cancer cells are well known to be 
energy hungry, activating molecular pathways of growth to multiply quickly. It has 
been found that fasting can improve outcomes for cancer patients [123]. The specific 
food that a cancer patient consumes, or lack thereof, can cause tumor starvation, 
have cancer-specific toxicity, activate anticancer immune response, or enhance 
drug-based therapy. Reducing calories have been shown to attack, stress, and kill 
cancer cells. Low calorie or ketogenic diets increase tumor-infiltrating CD8+ T cells 
[94, 124] and reduce immune inhibitory ligand expression such as PDL-1138 [125]. 
If NNS’s were used to decrease calories consumed in cancer patients the type and 
time of remaining calories consumed is still important. Modifying consumption 
of specific amino acids can be useful when treating cancer patients. For example, 
both glucose (sugar) and glutamine (protein) are central to cell growth (e.g. TCA 
cycle, Nucleotide synthesis, Cellular redox balance, Lipid synthesis) [123]. Glucose 
contributes pyruvate and acetyl-CoA to the TCA cycle while glutamine adds 
α-ketoglutarate, producing ATP and NADH which is used in oxidative phosphoryla-
tion to create even more ATP generation. Both glucose and glutamine are needed for 
different steps in nucleotide synthesis so lowering consumption of both will syner-
gistically inhibit cancer cells more that inhibition of either alone. Likewise glucose 
and glutamine work orthogonally to maintain cellular redox potential balance. 
Glucose is needed for NADPH production via the pentose-phosphate pathway, and 
glutamine in conjunction with NADPH forms the antioxidant GSH. Lipid synthesis 
needs both glucose for cytoplasmic acetyl-CoA and glutamine as a carbon source, 
particularly under hypoxic conditions which are common in tumors. Methionine 
restriction reduces one-carbon metabolism and nucleotide synthesis, thereby 
improving cancer inhibition by chemotherapy and radiation. Histidine catabolism 
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reduces cells levels of tetrahydrofolate, which is a cofactor in nucleotide synthesis. 
The cancer drug Methotrexate inhibits dihydrofolate reductase which generates 
tetrahydrofolate, therefore histidine supplementation could act synergistically with 
methotrexate in killing cancer cells [123]. Increasing arginine in mice was found to 
increase T-cell activation and T-cell mediated antitumor response [126].
All of these example diets with glucose and specific amino acids suggest a cancer 
patient on a high fat/low carb/low protein diet with NNS’s could have better out-
comes than if on a normal diet.. While NNS’s could increase adherence to such diets 
it is not currently known if such a diet would be any better than intermittent fasting 
for cancer patients [95, 98, 105, 127–130], and in fact intermittent fasting has been 
shown in analysis to have the best adherence of common diets.
NNS’s have been shown to increase death, though studies have varied largely in the 
magnitude of the effect. In 2018 Mulle et al. found NNS’s to cause more deaths than 
natural sugar. The study was done with a 451,743 cohort from across 10 European 
countries. Participants were fairly healthy and excluded if they had preexisting 
conditions (cancer, heart disease, stroke, or diabetes at baseline), with a mean (SD) 
age of 50.8 (9.8) years. The participants were mostly women (71.1%). Participants 
that consumed 2 or more glasses per day of total soft drinks (with NNS’s or sugar 
beverages, compared to <1 glass per month) died earlier (hazard ratio [HR], 1.17; 
95% CI, 1.11–1.22; P < .001). Sugar-sweetened soft drinks only had a HR of 1.08 (95% 
CI, 1.01–1.16; P = .004), compared to NNS’s with a HR of 1.26 (95% CI, 1.16–1.35; 
P < .001). While NNS’s seemed to increase participants risk of deaths from circula-
tory diseases (HR, 1.52; 95% CI, 1.30–1.78; P < .001), sugar-sweetened soft drinks 
increased deaths from digestive diseases (HR, 1.59; 95% CI, 1.24–2.05; P < .001) [121].
Some studies have found aspartame to be carcinogenic in large animal stud-
ies with rats [131, 132] and mice [131, 133] (many animals per sex and group of 
exposure, numerous dose levels tested, and with observation extending to death) 
[134]. In 2012 a prospective epidemiological study showed diet soda with aspartame 
to increase risk of non-Hodgkin’s lymphoma and multiple myeloma in men [135]. 
Some have theorized that increased aspartame consumption could be linked to an 
increase in brain tumors [136], but a later study looking at almost half a million 
people between 50 and 71 years of age found there to be no link between aspartame 
and either hematopoietic or brain cancer [137]. However, a metaanalysis of 22 
studies found aspartame to not cause cancer while looking at low, medium, and 
high doses in rodents, however it is worth noting that the odds ratio had an extraor-
dinarily large range from 0.115 to 3.500 [138]. While case control studies have found 
an increased risk of cancer, such as a relative risk (RR) 1.3 for bladder cancer from 
heavy sweetener consumption, the same study found heavy coffee consumption (50 
cups/week) had a RR of 1.4 for bladder cancer [34, 139]. While cancer can result in 
death, and therefore has large negative effects on Quality of Life Year calculations 
(QALYs), the data does not suggest NNS’s increased cancer risk as much as other 
diseases, such as circulatory disease and metabolic syndromes.
3. Conclusions
While the continually growing list of NNS’s still have many unanswered ques-
tions regarding their biological effect in humans, the knowledge we are gaining 
about each NNS continues to grow as well. Sucralose is now known to become 
acylated and accumulate in fat tissue. Future studies with sucralose could require 
long wash out periods, and consumers could expect a delay in biological changes 
if they removed sucralose from their diet. Aspartame holds a preferential spot 
among the major NSS’s in that it is quickly broken down when consumed so less 
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likely to have some of the deleterious effects by binding sweet receptors outside the 
oral cavity. Many NNS’s alter the gut biome, with sucralose and saccharin seeming 
particularly deleterious. Unlike aspartame, saccharin is very stable in vivo and binds 
sweet receptors in the GI tract. Sucralose on the other hand becomes acetylated and 
accumulates in fat tissue, thereby potentially posing side effects for days long than 
other NSS’s. The altered gut biome reduces satiety, causing consumption of more 
calories later. Obesity in mice has been alleviated through a fecal transplant which 
restores the gut biome [140]. This NNS induced dysbiosis also increases digestion of 
choline, needed for synthesis of VLDL which mobilizes fat from the liver. The cho-
line deficiency and decreased VLDL leads to metabolic issues such as non-alcoholic 
fatty liver disease (NAFLD) [60].
Future double-blind human studies that would benefit the field would test 
individual NNS’s to determine the causative effect of NNS consumption on:
1. Sleep quality and quantity (when consumed close to sleep)
2. Resting metabolic rate (RMR) during fasting
3. Energy expenditure (EI) during fasting
4. Autophagy during fasting
While the use of NNS’s primary goal (reduced obesity) appears discreet, the 
multiple interacting pathways involved in effecting that change make the cause 
and effect complex to disentangle (e.g. changing gut biome, leaky gut, NAFLD, 
increased appetite, decreased RMR).
Conflict of interest
The authors declare no conflict of interest.
Appendices and nomenclature
5-HT 5-hydroxytryptamine, (also) serotonin
Ace-K Acesulfame-potassium
ADI Acceptable Daily Intake
ADME Absorption, Distribution, Metabolism, and Excretion
AUC Area Under the Curve
CCK Cholecystokinin
CICO Calories-In-Calories-Out




FDA US Food and Drug Administration
GIP gastric inhibitory peptide, (also) glucose-dependent insulinotropic 
polypeptide
GERD Gastroesophageal Reflux Disease
GI Gastrointestinal
GLP-1 Glucagon-Like Peptide-1
GTT Glucose Tolerance Test
HbA1C Glycosylated Hemoglobin
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PPP Pentose Phosphate Pathway
PYY Peptide Tyrosine Tyrosine
MW Molecular Weight
NAFLD Nonalcoholic Fatty Liver Disease
NNS Non-Nutritional Sweetener
NOAEL No Observed Adverse Effect Level
QALY Quality Adjusted Life Year
RR Relative Risk
SCF European Union’s Scientific Committee for Food
TBW Total Body Weight
TMA Trimethylamine
USD United States of America Dollars
WWTP Waste Water Treatment Plant
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